JP2020516253A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516253A5
JP2020516253A5 JP2019554977A JP2019554977A JP2020516253A5 JP 2020516253 A5 JP2020516253 A5 JP 2020516253A5 JP 2019554977 A JP2019554977 A JP 2019554977A JP 2019554977 A JP2019554977 A JP 2019554977A JP 2020516253 A5 JP2020516253 A5 JP 2020516253A5
Authority
JP
Japan
Prior art keywords
ifng
immune score
gzmb
cd8a
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027561 external-priority patent/WO2018191660A1/en
Publication of JP2020516253A publication Critical patent/JP2020516253A/ja
Publication of JP2020516253A5 publication Critical patent/JP2020516253A5/ja
Pending legal-status Critical Current

Links

JP2019554977A 2017-04-14 2018-04-13 がんのための診断及び治療方法 Pending JP2020516253A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762485874P 2017-04-14 2017-04-14
US62/485,874 2017-04-14
US201862628227P 2018-02-08 2018-02-08
US62/628,227 2018-02-08
PCT/US2018/027561 WO2018191660A1 (en) 2017-04-14 2018-04-13 Diagnostic and therapeutic methods for cancer

Publications (2)

Publication Number Publication Date
JP2020516253A JP2020516253A (ja) 2020-06-11
JP2020516253A5 true JP2020516253A5 (enExample) 2021-05-27

Family

ID=62152649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554977A Pending JP2020516253A (ja) 2017-04-14 2018-04-13 がんのための診断及び治療方法

Country Status (10)

Country Link
US (1) US20200157635A1 (enExample)
EP (1) EP3610042A1 (enExample)
JP (1) JP2020516253A (enExample)
KR (1) KR20200005540A (enExample)
CN (1) CN110621787A (enExample)
AU (1) AU2018251993A1 (enExample)
CA (1) CA3058478A1 (enExample)
MX (1) MX2019012192A (enExample)
TW (1) TW201839400A (enExample)
WO (1) WO2018191660A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
US20190209652A1 (en) * 2016-09-23 2019-07-11 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
CA3052670A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2019394940A1 (en) * 2018-12-05 2021-06-24 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
JP2022514952A (ja) * 2018-12-19 2022-02-16 ストラータ オンコロジー， インコーポレイテッド チェックポイント阻害薬応答性がんを有する対象を検出及び処置する方法
US20220193211A1 (en) * 2019-04-18 2022-06-23 Intellistem Technologies Inc. Overexpression of immunoproteasome in host cells for generating antigen-presenting cells
CN114174537A (zh) * 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2021030156A1 (en) * 2019-08-09 2021-02-18 The Regents Of The University Of California Compositions and methods for diagnosis and treatment of bladder cancer
KR20220075351A (ko) * 2019-10-04 2022-06-08 씨젠 인크. 항-pd-l1 항체 및 항체-약물 접합체
TW202140568A (zh) * 2020-03-19 2021-11-01 日商中外製藥股份有限公司 用於預測檢查點抑制劑反應的生物標記
EP4127244A4 (en) * 2020-03-31 2024-09-11 Cedars-Sinai Medical Center BIOMARKER CHARTS FOR STRATIFICATION OF THE RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN CANCER
SE2050559A1 (en) * 2020-05-13 2021-11-14 Khs Biomedinvent Ab PD-1 as a predictive marker for therapy in cancer
WO2021252977A1 (en) * 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
CN113409949B (zh) * 2021-06-26 2022-09-02 南方医科大学南方医院 基于器官转移谱的非小细胞肺癌免疫检查点抑制治疗疗效的预测模型的构建方法及其应用
CN114694745A (zh) * 2022-03-24 2022-07-01 至本医疗科技（上海）有限公司 预测免疫疗效的方法、装置、计算机设备和存储介质
KR20250163916A (ko) * 2023-03-06 2025-11-21 제넨테크, 인크. 비소세포 폐암의 예후 및 치료 방법
JPWO2024225488A1 (enExample) * 2023-04-27 2024-10-31

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US8219149B2 (en) 2005-06-29 2012-07-10 Nokia Corporation Mobile communication terminal
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NO2504364T3 (enExample) 2009-11-24 2018-01-06
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2867588A1 (en) * 2012-03-30 2013-10-03 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
JP6312659B2 (ja) * 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
MX2015011386A (es) * 2013-03-15 2016-02-03 Oncomed Pharm Inc Metodo para tratar cancer pancreatico.
WO2014151006A2 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015095423A2 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US20170275347A1 (en) * 2014-09-05 2017-09-28 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy
EP3839510A3 (en) * 2015-04-17 2021-08-25 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
HK1248773A1 (zh) * 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法

Similar Documents

Publication Publication Date Title
Subbiah et al. The evolving landscape of tissue‐agnostic therapies in precision oncology
JP2018521976A5 (enExample)
JP2020513788A5 (enExample)
JP2019535237A5 (enExample)
IL255312B (en) Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
JP2022513685A5 (enExample)
JP2016539083A5 (enExample)
JP2020508317A5 (enExample)
RU2016141385A (ru) Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US12183434B2 (en) Diagnostic and therapeutic methods for cancer
US20170067116A1 (en) Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in Cancer
JP7481255B2 (ja) 抗体薬物複合体の感受性マーカー
AU2021358768A9 (en) Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
JP2018516244A5 (enExample)
JP2019531268A5 (enExample)
Park et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results
JP2024521105A (ja) 肺癌の処置用組成物及び方法
WO2011007787A1 (ja) 癌特異的膜抗原に対する抗体を含有する癌治療剤
Nakahama et al. Safe concurrent use of anti-tuberculosis drugs and pembrolizumab in a patient with non-small-cell lung cancer who was infected with mycobacterium tuberculosis
EP4330436A1 (en) Therapeutic and diagnostic methods and compositions for cancer
JP2024514506A5 (enExample)
CA3222362A1 (en) Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitory substance, and standard therapy
WO2020223233A1 (en) Prognostic and therapeutic methods for colorectal cancer
WO2017201142A1 (en) Treatment of lung adenocarcinoma
AU2018207719A1 (en) Method for treating cancer metastasis and composition thereof